High Profile Call Girls Kodigehalli - 7001305949 Escorts Service with Real Ph...
Novel Treatments
1. Novel Treatments for Osteoporosis Prof. Steven R. Cummings, MD San Francisco Coordinating Center Support from Novartis, Lilly, Organon, Pfizer, Amgen, NIH, Zelos
37. 4 years of Raloxifene decreased the risk of vertebral fracture* % with fracture Placebo RLX 60 RLX120 * Among women with vertebral fracture 36% 43%
38. 4 years of raloxifene did not decrease the risk of non-spine fractures % with fractures 0 6 12 18 24 30 36 15 10 5 0 Months Placebo Raloxifene RR = 0.93 (0.81, 1.06)
39. RUTH Trial: Raloxifene does not decrease the risk of CHD Barrett-Connor, N Engl J Med 2006;355:125
40. 5 years of tamoxifen reduced the risk of ER+, not ER- breast cancer Fisher et al. , J Natl Cancer Inst 1998;90:1371-88 # events 76%
41. • 5 years of tamoxifen continues to reduce breast cancer risk and mortality for at least 10 years after stopping treatment • Adverse effects (and costs) last only 5 years Early Breast Cancer Clinical Trialists Group. Lancet 2005;365:1687 Benefits Persist Off Treat
42. RUTH Trial: Raloxifene does not decrease the risk of CHD Barrett-Connor, N Engl J Med 2006;355:125
43. Lasofoxifene improved spine BMD more than raloxifene 3% 1.7% *p<0.05 vs placebo; †p<0.05 vs raloxifene. % Change From Baseline * * † Raloxifene 60 mg/d Lasofoxifene 0.25 mg/d Placebo
44.
45.
46.
47. Percent Change vs. Placebo p ≤ 0.001 for all -12.5 (-25.1, 0.1) -15.8 (-26.7, -4.9) C-reactive Protein -15.8 (-19.5,-12.0) -16.2 (-19.7,-12.7) LDL-cholesterol +3.0 (2.7, 3.4) +2.9 (2.6, 3.2) Fem neck BMD +3.1 (2.8, 3.5) +3.0 (2.6, 3.3) Spine BMD 0.5 0.25 Lasofoxifene, mg/d